Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Article
in En
| MEDLINE
| ID: mdl-29483101
Full text:
1
Database:
MEDLINE
Main subject:
Pyrazoles
/
Pyrimidines
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Protein Kinase Inhibitors
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2018
Type:
Article